Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of SM101/BAX 1810 in IgA nephropathy
2015-002345-64Phase 2Terminated
- Sponsor
- Baxalta
- Start
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of valziflocept in IgA nephropathy (IgAN) (3 arms), sponsored by Baxalta. Primary endpoint: Primary efficacy: mean percent change in proteinuria from baseline to week 24. Started Sep 2015; status: terminated.
02
Drugs
valziflocept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2015-002345-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002345-64.